CNBC's "Fast Money" Two Big Names Buck Today’s Market Trend… Plus More Bruises For Boeing 8/20/24
Aug 20, 2024
The market rally has stalled, but Netflix and Eli Lilly are soaring to new heights. Netflix's rise is attributed to its advertising model, while Eli Lilly shines with promising drug study results. Boeing faces more turbulence as it halts testing on its 777X amid leadership changes. Discussions on Trisepatide reveal its potential in diabetes prevention and impact on the pharmaceutical landscape. Amidst market volatility, investors are advised to tread carefully and monitor key indicators.
AI Snips
Chapters
Transcript
Episode notes
Market Outliers
- Netflix and Eli Lilly reached all-time highs, defying the market downturn.
- Netflix benefited from positive ad sales news, while Eli Lilly's weight loss drug showed promising results.
Mounjaro's Impact
- Eli Lilly's weight loss drug Mounjaro significantly reduces type 2 diabetes risk.
- This impacted other diabetes and obesity companies like Dexcom and Insulate.
Mounjaro's Potential
- Mounjaro's trial results resonate strongly within the medical community.
- The drug's potential to prevent diabetes may lead to increased insurance coverage.